Category: Research/Reports

IRA Could ‘Crush the 340B Margin,’ Force Transparency into Program, Says Adam Fein of Drug Channels

June 25, 2024 William Newton, Associate Editor/Senior Writer Views

Adam Fein, Ph.D., president of Drug Channels Institute, hosted a June 21 webinar that discussed the IRA's interaction with the 340B program.

The Inflation Reduction Act (IRA) may reduce 340B margins for certain high-cost drugs and drive more transparency into the program, an influential pharmaceutical supply chain analyst who has been a frequent 340B critic told an audience of stakeholders late last

…

CBO Analysts Say Drug Spending Through 340B Grew 19% Annually From 2010 to 2021, 340B Champion Points Finger at Drug Industry

June 21, 2024 Shannon Young, Associate Editor/Senior Writer Views

Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by 2021—a 19% annual increase—according to preliminary Congressional Budget Office estimates released this week.

Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Reform Could Generate Federal Savings, Says Consulting Firm That Has Conducted 340B Studies for Pharma Friendly Groups

June 11, 2024 Rich Daly, Editor in Chief Views

Avalere's Milena Sullivan told 340B Report that it's important to understand "the impact 340B reform could have on federal spending."

A federal legislative overhaul of the 340B program could provide Medicare savings for the federal government, according to a review [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Hospitals Prescribe Part D Drugs to a Much Higher Share of Vulnerable Populations, Says Hospital-Backed Report

May 23, 2024 Shannon Young, Associate Editor/Senior Writer Views

A hospital-funded study found 340B hospitals prescribe a higher share of Medicare Part D drugs to a higher share of vulnerable patients.

Medicare Part D beneficiaries who received retail and specialty drugs from prescribers at 340B disproportionate share hospitals (DSH) were more [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Drugs Reach 18% of Outpatient Drug Sales, Says PhRMA-Backed Research; Providers Say It is Misleading

May 21, 2024 Rich Daly, Editor in Chief Views

A PhRMA funded report found that 340B drugs grew to 18% of total outpatient branded drug sales in 2022. The figures were criticized by 340B providers and others as misleading.

340B drugs have steadily increased as a share of U.S. branded outpatient pharmaceutical sales and reached 18% of the total [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Sales Increased 17% to $124B in 2023, Drug Industry Consulting Firm Finds

May 16, 2024 Shannon Young, Associate Editor/Senior Writer Views

Analysts from IQVIA found that 340B wholesale acquisition cost sales increased by 17% from 2022 to 2023.

The 340B program continued to expand in 2023, exceeding $124 billion in wholesale acquisition cost (WAC) sales—up from $107 billion [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Study Finds Newer 340B Public Hospitals More Likely to Increase Unprofitable Service Lines Than Newer Non-Profit Hospitals

May 7, 2024 Shannon Young, Associate Editor/Senior Writer Views

Government-owned 340B hospitals recently enrolled in 340B were more likely to increase unprofitable services than new 340B nonprofit hospitals, a recent study found.

While newly enrolled 340B hospital entrants served higher numbers of Medicaid and rural patients than non-340B hospitals, government-owned 340B hospitals [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Group Critical of Medicare Negotiation and 340B Program Suggests 340B Providers May Avoid IRA Negotiated Lower-Cost Drugs

May 2, 2024 William Newton, Associate Editor/Senior Writer Views

The American Action Forum published a policy insight that suggested 340B providers could avoid IRA-negotiated lower-cost drugs.

Medicare Part D plans and 340B providers may avoid drugs with negotiated lower Medicare prices to maximize revenue from rebates, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Twenty-One Percent of 340B Hospitals Will Not Receive Lump Sum Payments: Research

April 30, 2024 Rich Daly, Editor in Chief Views

A JAMA research letter found that one-fifth of 340B hospitals will not receive repayment from Medicare for previous underpayments.

One-fifth of 340B hospitals will garner no repayment from Medicare for past underpayments, according to a recent analysis by a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

MedPAC Analysis Estimates Medicare Part B Payments to 340B Hospitals are Significantly Higher than Ceiling Prices

April 16, 2024 Shannon Young, Associate Editor/Senior Writer Views

A MedPAC analysis found that Medicare paid 340B hospitals significantly more than the ceiling price for dozens of medications in 2022.

Medicare paid hospitals substantially more—almost $4 billion in aggregate—than the 340B ceiling price costs for dozens of single-source drugs, biologics [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live